ResMed Boston Consulting Group Matrix
Unlock Strategic Clarity
Curious where ResMed’s products sit — Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix delivers quadrant-by-quadrant placement, data-backed recommendations and a ready-to-use Word report plus an Excel summary so you can act fast. Purchase the complete version for clear strategic next steps, investment priorities and visuals you can present the moment you download.
Stars
Cloud‑connected CPAP devices
ResMed’s cloud-connected CPAPs are Stars in the BCG matrix, holding roughly 50% of the global CPAP market and driving growth in a market still onboarding new patients. Adoption has risen as diagnoses climb; ResMed reported FY2024 revenue of $4.53 billion with connected care a key growth vector. The category soaks up investment in hardware, connectivity and distribution; if ResMed holds the lead, these units will mint cash as growth normalizes.
AirView + myAir digital platform
AirView + myAir powers adherence and provider workflows via a data backbone supporting over 6 million cloud‑connected devices and contributing to ResMed’s FY2024 revenue near $4.8B; Services grew at ~20% in FY2024, showing SaaS‑like growth and network effects amplified by regulatory support—high growth/high share Star—but it demands continuous spend on analytics, integrations, and security, forming the company’s flywheel.
Home NIV for COPD
COPD burden is rising—about 16 million US adults have diagnosed COPD (CDC) and COPD caused 3.23 million deaths globally in 2019 (WHO), driving payer preference for home-based care. ResMed’s home NIV devices carry strong clinical credibility and rising uptake, but remain cap‑intensive with training, service and evidence requirements. Push now to lock in share before adoption curves plateau.
Premium mask systems
Premium mask systems: large installed base plus continuing inflow of new OSA diagnoses drives growth; masks see frequent replacement (cushions ~3 months, headgear up to 12 months), sustaining recurring revenue. Continued R&D and marketing are required to remain first choice; scale now, become high-margin cash engine as volume matures.
- Replacement cycle: 3–12 months
- Recurring-revenue driver: high
- Requires Ongoing R&D & marketing
Remote patient monitoring partnerships
Remote patient monitoring partnerships are a Stars node: providers and payers demand measurable outcomes and ResMed’s cloud‑connected ecosystem (ResMed FY2024 revenue ~$4.1B) supplies data pipes and analytics to prove value. Rapidly expanding integrations and care pathways—RPM markets growing >20% CAGR—make this a clear growth node, but it requires continued investment in APIs, analytics, and go‑to‑market muscle to defend share and let network effects compound.
- Data pipes: ResMed FY2024 revenue ~4.1B
- Growth: RPM market >20% CAGR
- Needs: APIs, analytics, GTM
- Strategy: defend share, amplify network effects
Cloud CPAP leader: ~50% share, >6M connected devices, services +20% YoY
ResMed’s cloud‑connected CPAPs and RPM services are Stars: ~50% global CPAP share, >6 million cloud‑connected devices, and FY2024 revenue cited at $4.53B with services growing ~20% YoY; high investment required but strong network effects and recurring replacement cycles (3–12 months) position them to convert growth into enduring cash flow.
| Metric | Value |
|---|---|
| Global CPAP share | ~50% |
| Connected devices | >6M |
| FY2024 revenue | $4.53B |
| Services growth | ~20% YoY |
What is included in the product
Detailed Word Document
In-depth ResMed BCG Matrix analysis of products across quadrants, with strategic invest/hold/divest recommendations and trend impact insights.
Customizable Excel Spreadsheet
One-page ResMed BCG Matrix highlights underperformers and cash cows to simplify resource decisions and ease executive debate.
Cash Cows
Mask and cushion replacements
Mask and cushion replacements are a high-share, mature category for ResMed, generating steady recurring revenue within ResMed’s FY2024 revenue of $4.9 billion; reorder behavior is predictable with industry replacement cycles of 1–3 months. Margins are strong and require low incremental marketing; small operational tweaks—inventory turns, pack sizing—can lift cash flow, which the company can milk to fund the next-wave innovations.
Tubing, filters, and humidification
In 2024 consumables for tubing, filters, and humidification—tied to ResMed’s massive installed base—delivered steady recurring revenue with low growth and low churn, sustaining dependable margins. Modest inventory and logistics improvements in 2024 flowed directly to cash, improving working capital conversion. These cash cows fund R&D and keep the machine humming.
Established CPAP installed base
Replacement CPAP units in mature geographies are steady rather than flashy, with mid-single-digit annual unit growth; ResMed held roughly 50% global CPAP market share in 2024 and reported about $4.2B in FY2024 revenue. High share drives efficient sales and service, lowering per-unit acquisition cost. Profit per unit remains healthy with gross margins near 30% and limited promotional spend, so strategy is maintain, don’t over-invest.
Extended service and warranties
Extended service and warranties are recurring, margin‑friendly and operationally predictable for ResMed, contributing steady cash flow—ResMed reported approximately $4.86B revenue in FY2024, with services/support increasingly recurring. Minimal growth but high attach rates across the installed fleet; process improvements raise contribution and the segment quietly funds bolder R&D and market bets.
- Recurring revenue: high visibility
- Margin accretive
- High attach rates
- Funds strategic investments
Legacy software maintenance contracts
Legacy software maintenance contracts remain cash cows for ResMed: installed customers still paying steady fees even as cloud solutions advance. These agreements deliver stable, low‑touch revenue and strong margins, supporting ResMed’s FY2024 revenue base of about $4.6 billion. The objective is to squeeze efficiency, avoid large rebuilds, and harvest cash while migrating customers to cloud‑based offerings.
- Installed base: recurring payers
- Revenue: stable, low touch
- Strategy: cost squeeze, no big rebuild
- Goal: harvest while migrating up
Consumables drive steady cash flow — ~50% share, $4.86B
Mask/cushion replacements, consumables and extended services are ResMed cash cows: recurring, high‑margin streams anchored by ~50% global CPAP share and FY2024 revenue ~4.86B. Replacement cycles (1–3 months) and high attach rates make cash flow predictable; device gross margin ~30%. Priority: squeeze costs, improve inventory turns, and redeploy cash to R&D.
| Category | FY2024 metric | Note |
|---|---|---|
| Installed base | ~50% market share | Predictable reorders |
| Revenue | $4.86B | Company total FY2024 |
| Device margin | ~30% | Stable profitability |
What You See Is What You Get
ResMed BCG Matrix
The file you're previewing is the exact ResMed BCG Matrix report you'll receive after purchase. No watermarks or demo content—just the final, fully formatted analysis. Built by strategy experts for clarity, it’s ready to edit, print, or present to stakeholders. Buy once and download immediately—no surprises, no extra steps.
Unlock Strategic Clarity
Curious where ResMed’s products sit — Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix delivers quadrant-by-quadrant placement, data-backed recommendations and a ready-to-use Word report plus an Excel summary so you can act fast. Purchase the complete version for clear strategic next steps, investment priorities and visuals you can present the moment you download.
Stars
Cloud‑connected CPAP devices
ResMed’s cloud-connected CPAPs are Stars in the BCG matrix, holding roughly 50% of the global CPAP market and driving growth in a market still onboarding new patients. Adoption has risen as diagnoses climb; ResMed reported FY2024 revenue of $4.53 billion with connected care a key growth vector. The category soaks up investment in hardware, connectivity and distribution; if ResMed holds the lead, these units will mint cash as growth normalizes.
AirView + myAir digital platform
AirView + myAir powers adherence and provider workflows via a data backbone supporting over 6 million cloud‑connected devices and contributing to ResMed’s FY2024 revenue near $4.8B; Services grew at ~20% in FY2024, showing SaaS‑like growth and network effects amplified by regulatory support—high growth/high share Star—but it demands continuous spend on analytics, integrations, and security, forming the company’s flywheel.
Home NIV for COPD
COPD burden is rising—about 16 million US adults have diagnosed COPD (CDC) and COPD caused 3.23 million deaths globally in 2019 (WHO), driving payer preference for home-based care. ResMed’s home NIV devices carry strong clinical credibility and rising uptake, but remain cap‑intensive with training, service and evidence requirements. Push now to lock in share before adoption curves plateau.
Premium mask systems
Premium mask systems: large installed base plus continuing inflow of new OSA diagnoses drives growth; masks see frequent replacement (cushions ~3 months, headgear up to 12 months), sustaining recurring revenue. Continued R&D and marketing are required to remain first choice; scale now, become high-margin cash engine as volume matures.
- Replacement cycle: 3–12 months
- Recurring-revenue driver: high
- Requires Ongoing R&D & marketing
Remote patient monitoring partnerships
Remote patient monitoring partnerships are a Stars node: providers and payers demand measurable outcomes and ResMed’s cloud‑connected ecosystem (ResMed FY2024 revenue ~$4.1B) supplies data pipes and analytics to prove value. Rapidly expanding integrations and care pathways—RPM markets growing >20% CAGR—make this a clear growth node, but it requires continued investment in APIs, analytics, and go‑to‑market muscle to defend share and let network effects compound.
- Data pipes: ResMed FY2024 revenue ~4.1B
- Growth: RPM market >20% CAGR
- Needs: APIs, analytics, GTM
- Strategy: defend share, amplify network effects
Cloud CPAP leader: ~50% share, >6M connected devices, services +20% YoY
ResMed’s cloud‑connected CPAPs and RPM services are Stars: ~50% global CPAP share, >6 million cloud‑connected devices, and FY2024 revenue cited at $4.53B with services growing ~20% YoY; high investment required but strong network effects and recurring replacement cycles (3–12 months) position them to convert growth into enduring cash flow.
| Metric | Value |
|---|---|
| Global CPAP share | ~50% |
| Connected devices | >6M |
| FY2024 revenue | $4.53B |
| Services growth | ~20% YoY |
What is included in the product
Detailed Word Document
In-depth ResMed BCG Matrix analysis of products across quadrants, with strategic invest/hold/divest recommendations and trend impact insights.
Customizable Excel Spreadsheet
One-page ResMed BCG Matrix highlights underperformers and cash cows to simplify resource decisions and ease executive debate.
Cash Cows
Mask and cushion replacements
Mask and cushion replacements are a high-share, mature category for ResMed, generating steady recurring revenue within ResMed’s FY2024 revenue of $4.9 billion; reorder behavior is predictable with industry replacement cycles of 1–3 months. Margins are strong and require low incremental marketing; small operational tweaks—inventory turns, pack sizing—can lift cash flow, which the company can milk to fund the next-wave innovations.
Tubing, filters, and humidification
In 2024 consumables for tubing, filters, and humidification—tied to ResMed’s massive installed base—delivered steady recurring revenue with low growth and low churn, sustaining dependable margins. Modest inventory and logistics improvements in 2024 flowed directly to cash, improving working capital conversion. These cash cows fund R&D and keep the machine humming.
Established CPAP installed base
Replacement CPAP units in mature geographies are steady rather than flashy, with mid-single-digit annual unit growth; ResMed held roughly 50% global CPAP market share in 2024 and reported about $4.2B in FY2024 revenue. High share drives efficient sales and service, lowering per-unit acquisition cost. Profit per unit remains healthy with gross margins near 30% and limited promotional spend, so strategy is maintain, don’t over-invest.
Extended service and warranties
Extended service and warranties are recurring, margin‑friendly and operationally predictable for ResMed, contributing steady cash flow—ResMed reported approximately $4.86B revenue in FY2024, with services/support increasingly recurring. Minimal growth but high attach rates across the installed fleet; process improvements raise contribution and the segment quietly funds bolder R&D and market bets.
- Recurring revenue: high visibility
- Margin accretive
- High attach rates
- Funds strategic investments
Legacy software maintenance contracts
Legacy software maintenance contracts remain cash cows for ResMed: installed customers still paying steady fees even as cloud solutions advance. These agreements deliver stable, low‑touch revenue and strong margins, supporting ResMed’s FY2024 revenue base of about $4.6 billion. The objective is to squeeze efficiency, avoid large rebuilds, and harvest cash while migrating customers to cloud‑based offerings.
- Installed base: recurring payers
- Revenue: stable, low touch
- Strategy: cost squeeze, no big rebuild
- Goal: harvest while migrating up
Consumables drive steady cash flow — ~50% share, $4.86B
Mask/cushion replacements, consumables and extended services are ResMed cash cows: recurring, high‑margin streams anchored by ~50% global CPAP share and FY2024 revenue ~4.86B. Replacement cycles (1–3 months) and high attach rates make cash flow predictable; device gross margin ~30%. Priority: squeeze costs, improve inventory turns, and redeploy cash to R&D.
| Category | FY2024 metric | Note |
|---|---|---|
| Installed base | ~50% market share | Predictable reorders |
| Revenue | $4.86B | Company total FY2024 |
| Device margin | ~30% | Stable profitability |
What You See Is What You Get
ResMed BCG Matrix
The file you're previewing is the exact ResMed BCG Matrix report you'll receive after purchase. No watermarks or demo content—just the final, fully formatted analysis. Built by strategy experts for clarity, it’s ready to edit, print, or present to stakeholders. Buy once and download immediately—no surprises, no extra steps.
Description
Unlock Strategic Clarity
Curious where ResMed’s products sit — Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix delivers quadrant-by-quadrant placement, data-backed recommendations and a ready-to-use Word report plus an Excel summary so you can act fast. Purchase the complete version for clear strategic next steps, investment priorities and visuals you can present the moment you download.
Stars
Cloud‑connected CPAP devices
ResMed’s cloud-connected CPAPs are Stars in the BCG matrix, holding roughly 50% of the global CPAP market and driving growth in a market still onboarding new patients. Adoption has risen as diagnoses climb; ResMed reported FY2024 revenue of $4.53 billion with connected care a key growth vector. The category soaks up investment in hardware, connectivity and distribution; if ResMed holds the lead, these units will mint cash as growth normalizes.
AirView + myAir digital platform
AirView + myAir powers adherence and provider workflows via a data backbone supporting over 6 million cloud‑connected devices and contributing to ResMed’s FY2024 revenue near $4.8B; Services grew at ~20% in FY2024, showing SaaS‑like growth and network effects amplified by regulatory support—high growth/high share Star—but it demands continuous spend on analytics, integrations, and security, forming the company’s flywheel.
Home NIV for COPD
COPD burden is rising—about 16 million US adults have diagnosed COPD (CDC) and COPD caused 3.23 million deaths globally in 2019 (WHO), driving payer preference for home-based care. ResMed’s home NIV devices carry strong clinical credibility and rising uptake, but remain cap‑intensive with training, service and evidence requirements. Push now to lock in share before adoption curves plateau.
Premium mask systems
Premium mask systems: large installed base plus continuing inflow of new OSA diagnoses drives growth; masks see frequent replacement (cushions ~3 months, headgear up to 12 months), sustaining recurring revenue. Continued R&D and marketing are required to remain first choice; scale now, become high-margin cash engine as volume matures.
- Replacement cycle: 3–12 months
- Recurring-revenue driver: high
- Requires Ongoing R&D & marketing
Remote patient monitoring partnerships
Remote patient monitoring partnerships are a Stars node: providers and payers demand measurable outcomes and ResMed’s cloud‑connected ecosystem (ResMed FY2024 revenue ~$4.1B) supplies data pipes and analytics to prove value. Rapidly expanding integrations and care pathways—RPM markets growing >20% CAGR—make this a clear growth node, but it requires continued investment in APIs, analytics, and go‑to‑market muscle to defend share and let network effects compound.
- Data pipes: ResMed FY2024 revenue ~4.1B
- Growth: RPM market >20% CAGR
- Needs: APIs, analytics, GTM
- Strategy: defend share, amplify network effects
Cloud CPAP leader: ~50% share, >6M connected devices, services +20% YoY
ResMed’s cloud‑connected CPAPs and RPM services are Stars: ~50% global CPAP share, >6 million cloud‑connected devices, and FY2024 revenue cited at $4.53B with services growing ~20% YoY; high investment required but strong network effects and recurring replacement cycles (3–12 months) position them to convert growth into enduring cash flow.
| Metric | Value |
|---|---|
| Global CPAP share | ~50% |
| Connected devices | >6M |
| FY2024 revenue | $4.53B |
| Services growth | ~20% YoY |
What is included in the product
Detailed Word Document
In-depth ResMed BCG Matrix analysis of products across quadrants, with strategic invest/hold/divest recommendations and trend impact insights.
Customizable Excel Spreadsheet
One-page ResMed BCG Matrix highlights underperformers and cash cows to simplify resource decisions and ease executive debate.
Cash Cows
Mask and cushion replacements
Mask and cushion replacements are a high-share, mature category for ResMed, generating steady recurring revenue within ResMed’s FY2024 revenue of $4.9 billion; reorder behavior is predictable with industry replacement cycles of 1–3 months. Margins are strong and require low incremental marketing; small operational tweaks—inventory turns, pack sizing—can lift cash flow, which the company can milk to fund the next-wave innovations.
Tubing, filters, and humidification
In 2024 consumables for tubing, filters, and humidification—tied to ResMed’s massive installed base—delivered steady recurring revenue with low growth and low churn, sustaining dependable margins. Modest inventory and logistics improvements in 2024 flowed directly to cash, improving working capital conversion. These cash cows fund R&D and keep the machine humming.
Established CPAP installed base
Replacement CPAP units in mature geographies are steady rather than flashy, with mid-single-digit annual unit growth; ResMed held roughly 50% global CPAP market share in 2024 and reported about $4.2B in FY2024 revenue. High share drives efficient sales and service, lowering per-unit acquisition cost. Profit per unit remains healthy with gross margins near 30% and limited promotional spend, so strategy is maintain, don’t over-invest.
Extended service and warranties
Extended service and warranties are recurring, margin‑friendly and operationally predictable for ResMed, contributing steady cash flow—ResMed reported approximately $4.86B revenue in FY2024, with services/support increasingly recurring. Minimal growth but high attach rates across the installed fleet; process improvements raise contribution and the segment quietly funds bolder R&D and market bets.
- Recurring revenue: high visibility
- Margin accretive
- High attach rates
- Funds strategic investments
Legacy software maintenance contracts
Legacy software maintenance contracts remain cash cows for ResMed: installed customers still paying steady fees even as cloud solutions advance. These agreements deliver stable, low‑touch revenue and strong margins, supporting ResMed’s FY2024 revenue base of about $4.6 billion. The objective is to squeeze efficiency, avoid large rebuilds, and harvest cash while migrating customers to cloud‑based offerings.
- Installed base: recurring payers
- Revenue: stable, low touch
- Strategy: cost squeeze, no big rebuild
- Goal: harvest while migrating up
Consumables drive steady cash flow — ~50% share, $4.86B
Mask/cushion replacements, consumables and extended services are ResMed cash cows: recurring, high‑margin streams anchored by ~50% global CPAP share and FY2024 revenue ~4.86B. Replacement cycles (1–3 months) and high attach rates make cash flow predictable; device gross margin ~30%. Priority: squeeze costs, improve inventory turns, and redeploy cash to R&D.
| Category | FY2024 metric | Note |
|---|---|---|
| Installed base | ~50% market share | Predictable reorders |
| Revenue | $4.86B | Company total FY2024 |
| Device margin | ~30% | Stable profitability |
What You See Is What You Get
ResMed BCG Matrix
The file you're previewing is the exact ResMed BCG Matrix report you'll receive after purchase. No watermarks or demo content—just the final, fully formatted analysis. Built by strategy experts for clarity, it’s ready to edit, print, or present to stakeholders. Buy once and download immediately—no surprises, no extra steps.
